Cargando…

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

BACKGROUND: In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/rearrang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zi-Rong, Chueh, Chen-Han, Chiang, Nai-Jung, Tsai, Yi-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496386/ https://www.ncbi.nlm.nih.gov/pubmed/37697368 http://dx.doi.org/10.1186/s12962-023-00473-5

Ejemplares similares

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Pemigatinib for cholangiocarcinoma
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
por: Yukutake, Masanobu, et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
por: Gong, Xiaohua, et al.
Publicado: (2023)

Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan’s National Health Insurance Research Database
por: Hsu, Jason C., et al.
Publicado: (2018)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
por: Wadsley, Jonathan, et al.
Publicado: (2023)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
por: Shi, Guo‐Ming, et al.
Publicado: (2022)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma
por: Hempel, Louisa, et al.
Publicado: (2022)

The dental use by pediatric patients in the National Health Insurance of Taiwan in 2020
por: Cheng, Feng-Chou, et al.
Publicado: (2022)

Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
por: Puar, Akshan, et al.
Publicado: (2022)

Fungal Diseases in Taiwan—National Insurance Data and Estimation
por: Huang, Yu-Shan, et al.
Publicado: (2019)

Health care utilization and medical costs for childhood asthma in Taiwan: using Taiwan National Health Insurance Research Database
por: Wang, Jiu-Yao, et al.
Publicado: (2012)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Medical Risk Factors Associated with Cholangiocarcinoma in Taiwan: A Population-Based Case-Control Study
por: Chang, Jeffrey S., et al.
Publicado: (2013)

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies
por: Gong, Xiaohua, et al.
Publicado: (2021)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023)

Analysis of emergency dental visits of pediatric patients in the National Health Insurance of Taiwan in 2020
por: Cheng, Feng-Chou, et al.
Publicado: (2022)

The impact of universal National Health Insurance on population health: the experience of Taiwan
por: Lee, Yue-Chune, et al.
Publicado: (2010)

Household out-of-pocket medical expenditures and national health insurance in Taiwan: income and regional inequality
por: Chu, Tu-Bin, et al.
Publicado: (2005)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

The dental use for periodontal diseases under the national health insurance system in Taiwan in 2021
por: Cheng, Feng-Chou, et al.
Publicado: (2023)

The dental use for dental caries under the National Health Insurance system in Taiwan in 2020
por: Cheng, Feng-Chou, et al.
Publicado: (2023)

Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma
por: Cheng, Chi-Tung, et al.
Publicado: (2015)

Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004
por: Woung, Lin-Chung, et al.
Publicado: (2010)

The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998–2008: a nation-wide cancer registry-based study
por: Chiang, Nai-Jung, et al.
Publicado: (2014)

Isolation of cancer‐associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma
por: Sha, Meng, et al.
Publicado: (2018)

Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment
por: Lin, Yuli, et al.
Publicado: (2019)

Visit to Taiwan
por: Tsai, Y S
Publicado: (1994)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Overview of dental radiation technologists in Taiwan
por: Cheng, Feng-Chou, et al.
Publicado: (2022)

Incidence, subtypes, sex differences and trends of stroke in Taiwan
por: Tsai, Chung-Fen, et al.
Publicado: (2022)

Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of national health insurance dataset
por: Chen, Fang-Pey, et al.
Publicado: (2014)

Examining the types and payments of the disabilities of the insurants in the national farmers' health insurance program in Taiwan
por: Wang, Jiun-Hao, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_gf6dmbrcs9t4nt5fpg4jpim5e1